Months after striking SHP2 deal with AbbVie, Jacobio pulls in $174M+ from Hong Kong IPO
The seasoned crew at Jacobio has raised $174.1 million on its HKEX debut, fuelling a pipeline anchored by two AbbVie-partnered allosteric SHP2 inhibitors.
It’s significantly less than what the biotech was rumored to be seeking back in August — Bloomberg’s sources said it could be as much as $400 million — but Qiming, which has backed the biotech since its Series A, was happy about how it went from founding to IPO in just five years. At 12.34%, Qiming owned the largest chunk of stock in Jacobio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.